## **LABELLING**

### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

#### Carton label

### 1. Name of the medicinal product

[HA525 trade name]\*
Lamivudine/Tenofovir disoproxil fumarate 300 mg/300 mg Tablets

#### 2. Statement of active substance

Each film-coated tablet contains 300 mg lamivudine 300 mg tenofovir disoproxil fumarate (equivalent to tenofovir disoproxil 245 mg or 136 mg of tenofovir).

### 3. List of excipients

Contains lactose.

See patient information leaflet for further information.

### 4. Pharmaceutical form and contents

Film-coated tablets 30 tablets 90 tablets

### 5. Method and route of administration

Oral use

Read the patient information leaflet before use.

## 6. Special warning that the medicinal product must be stored out of the reach and sight of children

Keep out of the reach of children.

### 7. Other special warning(s), if necessary

### 8. Expiry date

EXP {MM/YYYY}

## 9. Special storage conditions

Do not store above 30°C. Protect from moisture.

# 10. Special precautions for disposal of unused medicinal products or waste materials derived from such medicinal products, if appropriate

\* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility. Page 2 of 5

## 11. Name and address of the supplier

Sun Pharmaceutical Industries Limited Sun House, 201 B/1 Western Express Highway Goregaon (East) Mumbai – 400063 India

## 12. WHO Reference Number (Prequalification Programme)

HA525

### 13. Manufacturer's batch number

<Batch> <Lot> {number}

## 14. (Advice on) General classification for supply

Medicinal product subject to medical prescription.

## 15. Instructions on use

# PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING HDPE bottle label

### 1. Name of the medicinal product

[HA525 trade name]<sup>†</sup> Lamivudine/Tenofovir disoproxil fumarate 300 mg/300 mg Tablets

#### 2. Statement of active substance

Each film-coated tablet contains 300 mg lamivudine 300 mg tenofovir disoproxil fumarate (equivalent to tenofovir disoproxil 245 mg or 136 mg of tenofovir).

### 3. List of excipients

Contains lactose.

See patient information leaflet for further information.

### 4. Pharmaceutical form and contents

Film-coated tablets 30 tablets 90 tablets

#### 5. Method and route of administration

Oral use

Read the patient information leaflet before use.

# 6. Special warning that the medicinal product must be stored out of the reach and sight of children

Keep out of the reach of children.

### 7. Other special warning(s), if necessary

### 8. Expiry date

EXP {MM/YYYY}

## 9. Special storage conditions

Do not store above 30°C. Protect from moisture.

# 10. Special precautions for disposal of unused medicinal products or waste materials derived from such medicinal products, if appropriate

## 11. Name and address of the supplier

Sun Pharmaceutical Industries Limited Sun House, 201 B/1

 $<sup>^\</sup>dagger$  Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility. Page 4 of 5

Western Express Highway Goregaon (East) Mumbai – 400063 India

## 12. WHO Reference Number (Prequalification Programme)

HA525

### 13. Manufacturer's batch number

<Batch> <Lot> {number}

## 14. (Advice on) General classification for supply

Medicinal product subject to medical prescription.

### 15. Instructions on use